Colfax Announces Public Offering of 14,000,000 Shares of Common Stock
March 15 2021 - 4:05PM
Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a
leading diversified technology company, announced today that it has
commenced an underwritten registered public offering of 14,000,000
shares of its common stock. In addition, Colfax intends to grant
the underwriters a 30-day option to purchase up to an additional
2,100,000 shares of its common stock. The offering is subject to
market and other customary conditions.
The Company intends to use the net proceeds of the offering
(after deducting the underwriting discounts and commissions and
other estimated expenses of the offering payable by the Company)
for working capital and other general corporate purposes, which may
include, among other things, capital expenditures and the repayment
of indebtedness.
Goldman Sachs & Co. LLC and Evercore ISI are acting as joint
lead book-running managers and representatives of the underwriters
for the offering. Morgan Stanley and UBS Investment Bank are also
acting as joint book-running managers for the offering.
The proposed offering is being made pursuant to a shelf
registration statement on Form S-3, including a base prospectus,
that was filed by Colfax with the Securities and Exchange
Commission (the “SEC”) and was automatically effective upon filing
on February 18, 2021. The proposed offering will be made only by
means of a preliminary prospectus supplement and the accompanying
base prospectus. A preliminary prospectus supplement relating
to and describing the terms of the offering will be filed with the
SEC and will be available on the SEC’s website located at
www.sec.gov. Copies of the preliminary prospectus supplement and
the accompanying prospectus relating to the securities being
offered may also be obtained, when available, from: Goldman Sachs
& Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York,
NY 10055, by telephone at (888) 474-0200, or by email:
ecm.prospectus@evercore.com; or Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, Second Floor,
New York, New York 10014; or UBS Securities LLC, Attention:
Prospectus Department, 1285 Avenue of the Americas, New York, NY
10019, by telephone at (888) 827-7275 or by emailing
ol-prospectus-request@ubs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Colfax Corporation
Colfax Corporation is a leading diversified
technology company that provides specialty medical technologies and
fabrication technology products and services to customers around
the world, principally under the DJO and ESAB brands. Colfax
believes that its brands are among the most highly recognized in
each of the markets that it serves. The Company uses its Colfax
Business System (“CBS”), a comprehensive set of tools, processes
and values, to create superior value for customers, shareholders
and associates. Colfax’s common stock is traded on the NYSE under
the ticker “CFX.”
CAUTIONARY NOTE CONCERNING FORWARD
LOOKING STATEMENTS
This press release contains forward-looking
statements, including forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements include, but are not limited to,
statements concerning the proposed offering and Colfax’s intended
use of proceeds from the offering, plans, objectives, expectations
and intentions and other statements that are not historical or
current fact. Forward-looking statements are based on Colfax’s
current expectations and involve risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied in such forward-looking statements. Factors that could
cause Colfax’s results to differ materially from current
expectations include, but are not limited to, risks related to the
impact of the COVID-19 global pandemic, including actions by
governments, businesses and individuals in response to the
situation, such as the scope and duration of the outbreak, the
nature and effectiveness of government actions and restrictive
measures implemented in response, material delays and cancellations
of medical procedures, supply chain disruptions, the impact on
creditworthiness and financial viability of customers, and other
impacts on Colfax’s business and ability to execute business
continuity plans, and the other factors detailed in Colfax’s
reports filed with the SEC, including its most recent Annual Report
on Form 10-K under the caption “Risk Factors,” as well as the other
risks discussed in Colfax’s filings with the SEC. In addition,
these statements are based on assumptions that are subject to
change. This press release speaks only as of the date hereof.
Colfax disclaims any duty to update the information herein.
Contact:Mike MacekVice
President, FinanceColfax
Corporation+1-302-252-9129investorrelations@colfaxcorp.com
Colfax (NYSE:CFX)
Historical Stock Chart
From Apr 2024 to May 2024
Colfax (NYSE:CFX)
Historical Stock Chart
From May 2023 to May 2024